HER2跨膜结构域(TMD)突变(V659/G660)稳定同源与异源二聚化,是肺腺癌中罕见的可靶向致癌驱动突变并对阿法替尼有应答
研究对8551例连续肺腺癌进行基于杂交捕获的综合基因组分析,检出15例(0.18%)HER2跨膜结构域突变(HER2V659E/D、HER2G660D),与HER2激酶域突变及其他致癌驱动互斥;4例接受阿法替尼治疗的患者中3例获持久临床应答。
要点
- 8551例肺腺癌中检出15例(0.18%)HER2跨膜结构域突变(HER2V659E/D、HER2G660D)。
- HER2跨膜结构域突变与HER2激酶域突变及其他致癌驱动互斥,仅2例(13%)合并HER2扩增。
- 4例接受阿法替尼治疗的肺腺癌患者中3例获持久临床应答。
核心结论
- HER2跨膜结构域突变是肺腺癌中罕见的、可靶向的独特驱动突变。
- 应广泛采用能检出包括HER2跨膜结构域突变在内的多种HER2变异的综合基因组分析,以识别可能从HER2靶向治疗中获益的患者。
研究设计与样本
- 前瞻性分析8551例连续肺腺癌,应个体治疗医生的要求、以制定治疗决策为目的,采用基于杂交捕获的综合基因组分析(CGP)。
主要发现
- 在8551例肺腺癌的综合基因组分析中检出15例(0.18%)HER2跨膜结构域突变(HER2V659E/D、HER2G660D)。
- HER2跨膜结构域突变与HER2激酶域突变及其他致癌驱动在肺腺癌中互斥。
- 仅2例(13%)HER2跨膜结构域突变病例合并Erb-b2受体酪氨酸激酶2基因(HER2)扩增。
- 结构分析显示,V659和G660位点突变为高极性谷氨酸、天冬氨酸或精氨酸,应稳定HER2活性构象下的同源二聚化和异源二聚化。
- 4例肺腺癌患者接受泛HER抑制剂阿法替尼治疗,其中2例携带HER2V659E、1例携带双重HER2V659E/G660R突变,3例获持久临床应答。
临床怎么用
- 原文结论提出应广泛采用能检出多种HER2变异的综合基因组分析,以识别可能从HER2靶向治疗中获益的患者。
- 原文报告阿法替尼治疗使4例肺腺癌患者中的3例获持久临床应答,其中2例携带HER2V659E、1例携带双重HER2V659E/G660R突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Erb-b2 receptor tyrosine kinase (HER2) transmembrane domain (TMD) mutations (HER2V659E, HER2G660D) have previously been identified in lung adenocarcinomas, but their frequency and clinical significance is unknown. METHODS: We prospectively analyzed 8551 consecutive lung adenocarcinomas using hybrid capture-based comprehensive genomic profiling (CGP) at the request of the individual treating physicians for the purpose of making therapy decisions. RESULTS: We identified 15 cases (0.18%) of HER2 TMD mutations (HER2V659E/D, HER2G660D) through CGP of 8551 lung adenocarcinomas. HER2 TMD mutations were mutually exclusive from HER2 kinase domain mutations and other oncogenic drivers in lung adenocarcinoma. Only two cases with HER2 TMD mutations (13%) had concurrent Erb-b2 receptor tyrosine kinase 2 gene (HER2) amplification. Structural analysis of HER2 TMD association revealed that mutations at positions V659 and G660 to the highly polar residues glutamic acid, aspartic acid, or arginine should stabilize homodimerization and heterodimerization of HER2 in the active conformation. Treatment with afatinib, a pan-HER inhibitor, resulted in durable clinical response in three of four patients with lung adenocarcinoma, with two harboring HER2V659E and one with double HER2V659E/G660R mutations. HER2 TMD mutations (V659 and G660) are found in other non-NSCLC malignancies, and analogous TMD mutations are also found in EGFR, HER3, and HER4. CONCLUSION: HER2 TMD mutations represent rare but distinct targetable driver mutations in lung adenocarcinoma. CGP capable of detecting diverse HER2 alterations, including HER2 TMD mutations, should be broadly adopted to identify all patients who may benefit from HER2-targeted therapies.
引用
- Ou SI, Schrock AB, Bocharov EV, et al. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. J Thorac Oncol. 2016. PMID: 27903463. doi:10.1016/j.jtho.2016.11.2224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。